RecruitingPhase 1NCT05562024

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

Studying Neuroblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Principal Investigator
Qiang Zhao, Doctor
Tianjin Medical University Cancer Institute and Hospital
Intervention
T cell injection targeting B7-H3 chimeric antigen receptor(biological)
Enrollment
24 target
Eligibility
1 years · All sexes
Timeline
2022 – 2039

Study locations (2)

Collaborators

Tianjin Medical University Cancer Institute and Hospital · Shandong Cancer Hospital and Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05562024 on ClinicalTrials.gov

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

See all trials for Neuroblastoma →

← Back to all trials